|

NKT5097 CDK2/CDK4 dual degrader Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • NiKang Therapeutics, Inc.1

Indications

  • CCNE1 Amplified Advanced Solid Tumors1
  • HR+ Breast Cancer1
  • Uterine Carcinosarcoma1
  • HR+/HER2- Breast Cancer1
  • Triple Negative Breast Cancer (TNBC)1

La Jolla, California1 trial

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

UC San Diego Moores Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.